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Abstract
Information is required about treatment outcomes of Gram-negative prosthetic joint infections treated with prosthesis retention and
surgical debridement, especially where bioﬁlm-active antibiotics such as ﬂuoroquinolones are used. The outcome of 17 consecutive
patients with an early Gram-negative prosthetic joint infection who had been treated with prosthesis retention and surgical debridement
was analysed. Enterobacteriaceae were isolated in 16 patients and infections were mixed with other organisms in 13 (76%) patients.
The median joint age was 17 days and the median duration of symptoms before debridement was 7 days. All patients initially received
intravenous b-lactam antibiotic therapy and 14 patients were then treated with oral ciproﬂoxacin. Treatment failure occurred in two
patients over a median period of follow-up of 28 months. In only one patient was a relapsed Gram-negative infection responsible for
the failure and this patient had not been treated with ciproﬂoxacin. The 2-year survival rate free of treatment failure was 94% (95% CI,
63–99%). Prosthesis retention with surgical debridement, in combination with antibiotic regimens including ciproﬂoxacin, was effective
and should be considered for patients with early Gram-negative prosthetic joint infection.
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Introduction
Gram-positive organisms are responsible for the majority of
cases of prosthetic joint infection (PJI); however, Gram-
negative bacilli also constitute a substantial proportion of
pathogens. To date, little information has been available
about treatment outcomes of Gram-negative PJI, but the
available literature does suggest that outcomes may be
worse compared with Gram-positive infections, especially if
the prosthesis is retained [1]. Recent evidence has suggested
improved outcomes with Gram-negative PJI where ﬂuoroqui-
nolones could be used [2]. Accordingly, the aim of this study
is to evaluate the efﬁcacy of treating early Gram-negative PJI
at an institution where the treatment protocol involves
retention of the prosthesis, surgical debridement and antibi-
otic regimens including ciproﬂoxacin.
Materials and Methods
Study design
The study was carried out at a single tertiary hospital in
Melbourne, Victoria, Australia, which conducted the largest
number of prosthetic joint replacements of any institution in
the state of Victoria over the study period. The study cohort
was identiﬁed from a prospectively compiled register of all
patients undergoing joint replacement surgery between 1998
and 2007. Information for this register was collected during
inpatient and outpatient visits before and after surgery; this
included patient demographics, clinical procedures, patient
outcomes and complications. Where necessary, further clini-
cal data were also collected retrospectively directly from the
patient’s medical record.
Study population
The study population consisted of all consecutive patients
with a ﬁrst episode of mono- or polymicrobial Gram-
negative PJI involving a hip or knee prosthesis where the
initial treatment was surgical debridement and prosthesis
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retention. Patients were excluded if the infected prosthesis
was a megaprosthesis for bone tumour surgery or if the pri-
mary surgical treatment was prosthesis removal. During the
study period, a protocol existed where ‘early’ Gram-negative
PJI (<3 months from implantation) or ‘haematogenous’
Gram-negative PJI (acute onset of symptoms in a previously
well-functioning joint >3 months from implantation) was
treated with retention of the prosthesis and surgical debride-
ment by arthrotomy. The subsequent antibiotic regimen con-
sisted of an initial period of intravenous b-lactam antibiotic
followed by a course of oral ciproﬂoxacin. The treating clini-
cian had the authority to vary from the treatment protocol
with regard to the number of surgical debridement proce-
dures and the duration of intravenous and oral antibiotics,
depending on the clinical situation. The exact reasons for
variation from the protocol were not always available from
the medical record.
Deﬁnitions
A Gram-negative PJI was deﬁned by the isolation of Gram-
negative bacilli from at least two deep, peri-prosthetic cul-
ture specimens; or the isolation of Gram-negative bacilli
from one specimen plus the presence of purulence around
the joint, a sinus tract communicating with the joint or acute
inﬂammation on histopathology of surgical specimens [3].
Treatment failure was deﬁned as persistence or recurrence
of symptoms or signs of prosthetic infection, the isolation of
the same or different organisms from subsequent operative
samples or the removal of the prosthesis while antibiotic
therapy continued.
Microbiological methods
Susceptibility testing of isolates was performed according to
CLSI (NCCLS) guidelines. The MicroScan WalkAway (Dade
Behring Inc., Deerﬁeld, IL, USA) and agar dilution methods
were used for isolates from 1998 to 1999 and the Vitek-2
(bioMerieux, Marcy l’Etoile, France) was used for isolates
from 2000 until 2007.
Statistical analysis
The Kaplan–Meier method was used to estimate the 2-year
survival rate free of treatment failure. A Fisher exact test
was used for analysing categorical data.
Results
Study population
Over the study period 1919 total knee replacement and
1912 total hip replacement operations were performed at
this institution. Ninety patients were identiﬁed as having a
prosthetic knee (41) or hip (49) joint infection and of these
21 (23%) involved a Gram-negative bacillus. Gram-negative
PJI were more likely to involve a hip prosthesis than a knee
(17 vs 4; p 0.006). Four of the patients with Gram-negative
infections were excluded from further examination in this
study because they underwent either prosthesis removal
(two patients) or exchange (two patients) as the primary
surgical treatment. All four of these patients had a ‘late’ PJI,
with a median joint age of 38 months at the time of surgical
intervention.
The remaining 17 patients met the inclusion criteria and
formed the study population. Characteristics of individual
patients and their outcomes can be seen in Table 1. The
median age was 75 years (range 65–91 years). Fifteen
patients had a hip PJI and two patients had a knee PJI. The
original indication for joint replacement surgery was osteo-
arthritis in 14 patients, aseptic loosening of a previous
prosthesis in two patients and avascular necrosis of the
femoral head in one patient. Four patients had a fully
cemented prosthesis, two had a non-cemented prosthesis
and 11 had a cemented femoral stem/non-cemented acetab-
ular cup hip prosthesis. Two patients were immunosup-
pressed, two had malignancies, two had chronic renal
failure, two had type 2 diabetes mellitus and one had rheu-
matoid arthritis.
The median duration from prosthesis insertion until ﬁrst
debridement (joint age) was 17 days (range 9–1435). The
median duration of symptoms until debridement was 7 days
(range 1–19). The median time from diagnosis of infection
until debridement was <1 day (range 0–6 days).
Microbiology
Enterobacteriaceae were isolated in 16 patients. Escherichia
coli (ﬁve patients) and Proteus mirabilis (ﬁve patients) were
the most frequently isolated organisms. Pseudomonas aerugin-
osa was isolated in only two patients. All Gram-negative iso-
lates were susceptible to ciproﬂoxacin. Infections were
mixed with other organisms in 13 (76%) patients. In these
mixed infections, staphylococci were isolated on 10 occa-
sions and enterococci on ﬁve occasions.
Surgical treatment
The median number of debridement operations per patient
was three (range one to six). All debridements were
performed by open arthrotomy and involved a change of
the polyethylene liner, removal of infected soft tissue and
washout of the joint under high-pressure pulsatile lavage.
There were no major surgical complications noted as a
consequence of the debridement operations.
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Medical treatment
All patients in the study population received an initial
course of intravenous antibiotics followed by oral antibiotic
therapy. The median duration of intravenous antibiotic
treatment was 40 days (range 9–79 days). The intravenous
antibiotic used for treatment of the Gram-negative infec-
tion was a second- or third-generation cephalosporin in 11
patients, meropenem in seven patients and ertapenem in
three patients. Nine patients in addition received intrave-
nous vancomycin for initial treatment of mixed infections
with staphylococci and three patients received intravenous
benzylpenicillin for treatment of mixed infections with
enterococci. The median duration of inpatient hospital stay
for treatment of the infection was 23 days (range 9–
57 days). Two patients experienced a rash while receiving
intravenous antibiotics, leading to an earlier change to oral
antibiotics. The median duration of oral antibiotic treat-
ment was 12 months (range 1–55 months). Ciproﬂoxacin
was used for oral treatment of the Gram-negative infection
in 14 patients and amoxycillin/clavulanic acid was used in
three patients. Rifampicin-based oral regimens were used
in addition for mixed staphylococcal infections in nine
patients.
Three patients experienced transient nausea while taking
oral antibiotics; however, treatment was continued in each
of these. In another three patients, oral antibiotic treatment
was modiﬁed or shortened because of side effects or non-
compliance. In two patients, the oral antibiotic treatment is
ongoing with the intention of long-term suppression.
Follow-up
The median duration of follow-up was 28 months (range 2–
99 months) from the time of infection. The median time of
follow-up after stopping antibiotics was 12 months. One
patient died from unrelated causes 2 months after infection.
Outcomes
All 17 patients retained the original prosthesis at the time of
last review. There was no evidence of treatment failure in 15
patients. The 2-year survival rate free of treatment failure
was 94% (95% CI, 63–99%). One patient (patient 1) with a
mixed Klebsiella pneumoniae and methicillin-resistant Staphylo-
coccus epidermidis hip prosthesis infection developed relapsed
Klebsiella pneumoniae infection 6 years later. Staphylococcus
epidermidis was not isolated at the time of relapse. This
patient had been treated with 7 weeks of intravenous ceftri-
axone and then oral amoxicillin/clavulanic acid, rifampicin and
fusidic acid but was non-compliant with the oral antibiotics
after 4 months. Another patient (patient 11), with a mixed
methicillin-resistant Staphylococcus aureus (MRSA), E. coli and
Proteus mirabilis hip prosthesis infection, developed relapsed
MRSA infection 6 months after ceasing antibiotic therapy and
in the setting of new immunosuppression for myasthenia gra-
vis. Neither E. coli nor Proteus mirabilis were isolated at the
time of relapse. The relapsed infection was treated with fur-
ther debridement and the patient remained well on follow-
up while taking long-term suppressive oral antibiotics for the
MRSA infection.
Discussion
The approach to treatment of Gram-negative PJI with
debridement and prosthesis retention, combined with an
intravenous then oral antibiotic regimen was successful in
this study, with only two of 17 patients failing treatment.
The 2-year survival rate free of treatment failure of 94%
compares favourably with other studies examining outcomes
for early Gram-positive PJI. Evidence has been limited with
regard to outcomes for Gram-negative PJI and to date has
shown variable results [1]; however, outcomes have been
better where ﬂuoroquinolones have been used in the antibi-
otic regimen [2,4]. Notably, most patients in this study had
been treated with a ﬂuoroquinolone and the one patient
who had a relapsed Gram-negative infection was not treated
with a ﬂuoroquinolone, albeit with a treatment course
shorter than intended.
The importance of treating Gram-positive prosthesis
infections with antibiotics that have good activity against
bioﬁlm-associated organisms, such as rifampicin, has been
well established [5]. For Gram-negative infections, most
in vitro evidence shows that ﬂuoroquinolones have better
activity than other antibiotics in killing and preventing attach-
ment of slow-growing bioﬁlm-associated organisms [6–9].
Links have been made between better clinical outcomes and
in vitro activity of antibiotics including ﬂuoroquinolones
against bioﬁlm-associated organisms in chronic pulmonary
infections, where bioﬁlms also play an important role in path-
ogenesis [10]. In addition, good oral bioavailability, tolerance
and penetration into joint ﬂuid mean that ﬂuoroquinolones
are well suited for use in PJI.
A limitation to the use of ﬂuoroquinolones in this setting
is the potential for selecting resistant mutants during therapy,
in particular for Pseudomonas spp. [11]. To minimize this, a
period of intravenous b-lactam antibiotic was given to
patients in this study with the intention of reducing the bac-
terial load before starting ciproﬂoxacin. Given the growing
evidence of the beneﬁts of ﬂuoroquinolones, especially early
in the infection when bioﬁlms are being established, a rea-
sonable approach would also be to use combination b-lactam
CMI Aboltins et al. Gram-negative prosthetic joint infection 865
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 862–867
and ﬂuoroquinolone treatment early before continuing
longer term with ﬂuoroquinolone monotherapy. In the lim-
ited number of patients where this approach has been used
previously there has been good success [2,4].
At our institution, rates of ﬂuoroquinolone resistance
were low and all Gram-negative isolates in this study were
susceptible. A limitation to the use of ﬂuoroquinolones
elsewhere would be the high rates of ﬂuoroquinolone
resistance among Gram-negative isolates in many centres
[12].
In this study Gram-negative infections were signiﬁcantly
more likely to involve hip prostheses than knee prostheses
and the species of Gram-negative organisms were mostly
Enterobacteriaceae, often mixed with other bacteria inclu-
ding enterococci. These ﬁndings are consistent with the
likely colonization of the hip and groin area with gut-derived
organisms. To our knowledge this has not been reported
previously for Gram-negative PJI and needs to be conﬁrmed;
however, a non-signiﬁcant trend towards polymicrobial infec-
tions in hip PJI compared with knee PJI has been previously
described [13]. This raises the question of the need for
perioperative antimicrobial prophylaxis that covers Gram-
negative and other gut-derived organisms for higher-risk
patients undergoing total hip joint replacement.
In previous studies investigating outcomes for prosthesis
retention and debridement, treatment protocols in general
involved only one surgical debridement operation, with
repeated debridement only if there were ongoing signs of
infection [2,14,15]. At our institution, recognizing the impor-
tance of early disruption of bioﬁlms, repeated debridement
was encouraged even if clinical progress was adequate,
resulting in a median of three debridement operations per
patient. Although difﬁcult to separate from other issues, this
may have been a factor in the favourable outcomes in this
cohort. There were no major complications from the surgi-
cal treatment in this group of patients; however, given the
potential for increased morbidity with repeated operations
further research is warranted into this issue.
The duration of symptoms before surgical debridement is
a well-established risk factor for failure of treatment, with
some studies showing an increased risk of failure when
debridement was delayed by >2 days after symptom onset
[3]. In our study, the short median duration of symptoms of
7 days probably contributed to the good outcomes. Several
factors at our institution played a role in this, including a
co-located postoperative rehabilitation facility enabling early
review and protocols encouraging prompt debridement
surgery upon diagnosis of infection.
Although further larger, controlled studies that include
functional outcomes are required, this study suggests that
debridement without prosthesis removal combined with anti-
biotic regimens involving ﬂuoroquinolones is effective in the
treatment of early Gram-negative PJI.
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